Aurinia Completes Kezar Takeover at $6.955 Per Share Plus CVR
Aurinia acquired about 80.2% of Kezar’s shares for $6.955 cash each plus a CVR, completing the deal on May 11, 2026. Kezar becomes a wholly owned subsidiary.
Rà soát kỹ thông tin trước khi đưa vào ứng dụng thực tế
TL;DR: Aurinia finalized its takeover of Kezar Life Sciences, acquiring roughly 80.2% of the company’s outstanding shares for $6.955 in cash per share plus one contingent value right (CVR) each. The deal closed on May 11, 2026, making Kezar a wholly owned subsidiary of Aurinia.
Context
Aurinia launched the tender offer in early April 2026 to gain full control of Kezar, a biotech focused on autoimmune disease therapies. The offer set a minimum tender condition that required a substantial fraction of shares to be submitted.
By the expiration date, investors had tendered 5.93 million shares, representing about 80.24% of Kezar’s stock outstanding at that time. This level of participation satisfied the threshold and allowed Aurinia to proceed with the purchase.
Key Facts
The offer price consisted of $6.955 cash per share and one non‑transferable CVR for each share tendered. Each CVR entitles the holder to a future cash payment if Kezar achieves predefined milestones, such as regulatory approval or sales targets for its pipeline assets.
Approximately 5.93 million shares, or 80.24% of Kezar’s outstanding shares, were validly tendered and not withdrawn. Aurinia completed the acquisition on May 11, 2026, after the offer expired, and immediately integrated Kezar as a wholly owned subsidiary.
What It Means
The cash component provides Aurinia with immediate liquidity to fund integration costs and support ongoing research programs. The CVR structure defers part of the consideration, aligning Aurinia’s payout with Kezar’s future performance and reducing upfront risk.
With control exceeding 80%, Aurinia can consolidate decision‑making, streamline duplicate functions, and exercise full governance over Kezar’s intellectual property and manufacturing assets. The transaction reflects a common biotech strategy of mixing upfront cash with contingent rights to balance valuation uncertainty.
Analysts note that the success of the deal will depend on how quickly Aurinia can realize synergies and whether the CVR conditions are met.
Investors will monitor Kezar’s upcoming clinical trial readouts and any regulatory decisions that could trigger CVR payments, as well as Aurinia’s progress in merging the two companies’ pipelines and cost structures.
Continue reading
More in this thread
Conversation
Reader notes
Loading comments...